1. Pink Sheet
  2. >>Market Access

Part D Catastrophic Coverage: Manufacturers Could Agree To Increased ‘Liability’

 
• By Cathy Kelly

But drug makers want their financial contribution to go toward reducing beneficiary costs, not to replace plans’ insurance risk, according to comments submitted to two House committees on draft legislation.

Hands of an old man counting expenses on medicine and fees .Count the pennies. - Image
House Draft Bill Would Cap Medicare Part D Drug Costs

Prescription drug makers are amenable to shouldering some costs in the catastrophic phase of the Medicare Part D benefit to help create a spending cap for beneficiaries, according to industry comments on draft legislation being developed by the House Way and Means and Energy and Commerce committees.

The draft bill, released by the committees on 24 May, would set a cap on beneficiary cost sharing at the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

US FDA Could Seek Stronger Warnings On SSRI Antidepressant Risks During Pregnancy

 
• By Sue Sutter

Testimony during a July 21 ‘expert panel’ could help justify stronger warnings across the class about potential adverse effects on mother and baby. Panelists ranged from clinicians who said depression during pregnancy should be treated, to those who said sadness has been “medicalized."

World’s First Hemato-Oncology Microbiota Therapeutic Among Latest New EU Filings

 
• By Neena Brizmohun

The European Medicines Agency has started reviewing for potential EU marketing approval six new products, including MaaT Pharma’s microbiota therapeutic for acute-graft-versus-host disease, and AstraZeneca's camizestrant for locally advanced or metastatic breast cancer.

Sponsors Asked, EMA Delivered: One Handbook To Navigate CTIS

 
• By Vibha Sharma

The European Medicines Agency has revised the sponsor handbook for the Clinical Trials Information System, bringing together guidance that was previously scattered across multiple platforms and documents to help sponsors navigate the trial process more efficiently.